Design and Validation of Nanofibers Made of Self-Assembled Peptides to Become Multifunctional Stimuli-Sensitive Nanovectors of Anticancer Drug Doxorubicin.

cell-penetrating peptides magnetic nanoparticles self-assembling peptides triple negative breast cancer

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
25 Jul 2022
Historique:
received: 28 06 2022
revised: 13 07 2022
accepted: 21 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Self-assembled peptides possess remarkable potential as targeted drug delivery systems and key applications dwell anti-cancer therapy. Peptides can self-assemble into nanostructures of diverse sizes and shapes in response to changing environmental conditions (pH, temperature, ionic strength). Herein, we investigated the development of self-assembled peptide-based nanofibers (NFs) with the inclusion of a cell-penetrating peptide (namely gH625) and a matrix metalloproteinase-9 (MMP-9) responsive sequence, which proved to enhance respectively the penetration and tumor-triggered cleavage to release Doxorubicin in Triple Negative Breast Cancer cells where MMP-9 levels are elevated. The NFs formulation has been optimized via critical micelle concentration measurements, fluorescence, and circular dichroism. The final nanovectors were characterized for morphology (TEM), size (hydrodynamic diameter), and surface charge (zeta potential). The Doxo loading and release kinetics were studied in situ, by optical microspectroscopy (fluorescence and surface-enhanced Raman scattering-SERS). Confocal spectral imaging of the Doxo fluorescence was used to study the TNBC models in vitro, in cells with various MMP-9 levels, the drug delivery to cells as well as the resulting cytotoxicity profiles. The results confirm that these NFs are a promising platform to develop novel nanovectors of Doxo, namely in the framework of TNBC treatment.

Identifiants

pubmed: 35893800
pii: pharmaceutics14081544
doi: 10.3390/pharmaceutics14081544
pmc: PMC9331957
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Vinci (France)
ID : C2-984
Organisme : Programma Star Plus 2020
ID : 21-UNINA-EPIG-071
Organisme : Fondazione Umberto Veronesi
ID : xxx

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Cells. 2019 Aug 22;8(9):
pubmed: 31443516
Pharmacol Ther. 2019 Jul;199:30-57
pubmed: 30825473
Int J Mol Sci. 2015 Oct 23;16(10):25323-37
pubmed: 26512649
Int J Nanomedicine. 2015 Mar 10;10:1885-98
pubmed: 25792823
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Nature. 2012 Jun 20;486(7403):405-9
pubmed: 22722202
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Chem Soc Rev. 2008 May;37(5):993-1000
pubmed: 18443684
Bioconjug Chem. 2018 May 16;29(5):1553-1559
pubmed: 29553717
Sci Adv. 2020 Apr 15;6(16):eaay9035
pubmed: 32490199
Ann Oncol. 2012 Dec;23(12):2997-3006
pubmed: 23166150
Chem Rev. 2013 Mar 13;113(3):1391-428
pubmed: 23273312
J Med Chem. 2021 Aug 12;64(15):11675-11694
pubmed: 34296619
Eur J Pharm Sci. 2017 Aug 30;106:287-293
pubmed: 28579004
Angew Chem Int Ed Engl. 2009;48(32):5921-6
pubmed: 19582740
Small. 2013 Mar 25;9(6):853-62
pubmed: 23135878
Int J Pharm. 2017 Aug 7;528(1-2):322-333
pubmed: 28606508
J Pept Sci. 2017 Apr;23(4):272-281
pubmed: 28139012
Int J Nanomedicine. 2013;8:1989-99
pubmed: 23717042
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
pubmed: 17092599
Biotechnol Bioeng. 2015 Mar;112(3):601-11
pubmed: 25220931
Int J Pharm. 2006 Jan 3;307(1):93-102
pubmed: 16303268
Pharmaceutics. 2022 Jun 10;14(6):
pubmed: 35745807
Curr Oncol Rep. 2018 Jun 6;20(8):61
pubmed: 29876677
Biomaterials. 2019 Mar;197:284-293
pubmed: 30677557
J Biomol NMR. 1995 Jul;6(1):1-10
pubmed: 22911575
Curr Drug Metab. 2012 Jan;13(1):93-104
pubmed: 22292812
J Pept Sci. 2000 Jun;6(6):264-70
pubmed: 10912906
Sci Rep. 2018 Sep 14;8(1):13836
pubmed: 30218088
CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62
pubmed: 24114568
Int J Pharm. 2016 Oct 15;512(1):1-13
pubmed: 27521706
Adv Drug Deliv Rev. 2021 May;172:127-147
pubmed: 33705872
Nanotechnology. 2008 Nov 19;19(46):465608
pubmed: 21836255
Clin Breast Cancer. 2013 Dec;13(6):416-20
pubmed: 24099649
Biomacromolecules. 2019 Mar 11;20(3):1362-1374
pubmed: 30735368

Auteurs

Valentina Del Genio (V)

Department of Pharmacy, School of Medicine, University of Naples 'Federico II', Via Domenico Montesano 49, 80131 Naples, Italy.
EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200 Tours, France.

Annarita Falanga (A)

Department of Agricultural Science, University of Naples 'Federico II', Via Università 100, 80055 Portici, Italy.

Emilie Allard-Vannier (E)

EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200 Tours, France.

Katel Hervé-Aubert (K)

EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200 Tours, France.

Marilisa Leone (M)

Institute of Biostructures and Bioimaging-CNR, 80145 Naples, Italy.

Rosa Bellavita (R)

Department of Pharmacy, School of Medicine, University of Naples 'Federico II', Via Domenico Montesano 49, 80131 Naples, Italy.

Rustem Uzbekov (R)

Plateforme Scientifique et Technique "Analyse des Systèmes Biologiques" (PST ASB), UFR de Médecine, 37032 Tours, France.
Faculty of Bioengineering and Bioinformatics, Moscow State University, 119992 Moscow, Russia.

Igor Chourpa (I)

EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200 Tours, France.

Stefania Galdiero (S)

Department of Pharmacy, School of Medicine, University of Naples 'Federico II', Via Domenico Montesano 49, 80131 Naples, Italy.

Classifications MeSH